November 18, 2024Interim Report for January-September 2024
August 29, 2024Interim Report for January-June 2024
May 30, 2024Interim Report for January-March 2024
February 29, 2024Year-end report for 2023
February 29, 2024Annual Review 2023
February 29, 2024Financial Statements 2023 (Finnish)
January 26, 2024Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
January 9, 2024Nanoform Management Presentation - SEB Nordic Seminar Copenhagen
Questions from investors, analysts and journalists
